Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: A preliminary report

BMC Biotechnology

Volumn 11, Issue , 2011, Pages

  Ventura, Elisa ^a,b   Balza, Enrica ^c   Borsi, Laura ^c   Tutolo, Giorgia ^a   Carnemolla, Barbara ^c   Castellani, Patrizia ^c   Zardi, Luciano ^a  

^a CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS PROCESS; ANTI-INFLAMMATORY PROTEINS; BIODISTRIBUTIONS; DRUG EFFICACY; EXTRACELLULAR; FUSION PROTEINS; HOMODIMERIC PROTEINS; IN-VIVO; INFLAMMATORY DISEASE; ISOFORMS; LIGAND BINDING; RECOMBINANT PROTEIN; RESIDENCE TIME; RHEUMATOID ARTHRITIS; TARGETED DELIVERY; THERAPEUTIC INDEX; TISSUE REMODELING; UTEROGLOBIN; VASCULATURE;

BLOOD; DISEASE CONTROL; GLYCOPROTEINS; HISTOLOGY; LIGANDS; PROTEINS; TISSUE;

SCAFFOLDS (BIOLOGY);

COLLAGEN ANTIBODY; FIBRONECTIN; HYBRID PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY L19; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR P75; UNCLASSIFIED DRUG; UTEROGLOBIN; ED B FIBRONECTIN PROTEIN, HUMAN; ED-B FIBRONECTIN PROTEIN, HUMAN; RADIOACTIVE IODINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG EFFICACY; IMMUNOREACTIVITY; LIGAND BINDING; MOUSE; NONHUMAN; PANNUS; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RHEUMATOID ARTHRITIS; SOFT TISSUE INFLAMMATION; SYMPTOMATOLOGY; VASCULARIZATION; ANIMAL; ARTHRITIS; CHEMISTRY; CHO CELL; DIMERIZATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; GENETIC TRANSFECTION; GENETICS; HAMSTER; HUMAN; IMMUNOLOGY; JOINT; METABOLISM; METHODOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PLASMID; PROTEIN BINDING; TERATOCARCINOMA;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CHO CELLS; CRICETINAE; DIMERIZATION; DRUG DELIVERY SYSTEMS; FIBRONECTINS; HUMANS; IODINE RADIOISOTOPES; JOINTS; MICE; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT FUSION PROTEINS; TERATOCARCINOMA; TRANSFECTION; TUMOR NECROSIS FACTOR-ALPHA; UTEROGLOBIN;

EID: 80755125817     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-11-104     Document Type: Article

References (30)

1. Feldmann M, Maini RN. Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003, 9(10):1245-1250. 10.1038/nm939, 14520364.
2. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumour necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117(2):244-279. 10.1016/j.pharmthera.2007.10.001, 18155297.
3. Nestorov I. Clinical pharmacokinetics of tumour necrosis factor antagonists. J Rheumatol Suppl 2005, 74:13-18.
4. Neve R, Kissonerghis M, Clark J, Feldmann M, Chernajovsky Y. Expression of an efficient small molecular weight tumour necrosis factor/lymphotoxin antagonist. Cytokine 1996, 8(5):365-370. 10.1006/cyto.1996.0050, 8726664.
5. Hughes C, Faurholm B, Dell'Accio F, Manzo A, Seed M, Eltawil N, Marrelli A, Gould D, Subang C, Al-Kashi A, et al. Human single-chain variable fragment that specifically targets arthritic cartilage. Arthritis Rheum 62(4):1007-1016.
6. Zardi L, Carnemolla B, Siri A, Petersen TE, Paolella G, Sebastio G, Baralle FE. Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon. EMBO J 1987, 6(8):2337-2342. 553637, 2822387.
7. Carnemolla B, Balza E, Siri A, Zardi L, Nicotra MR, Bigotti A, Natali PG. A tumour-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol 1989, 108(3):1139-1148. 10.1083/jcb.108.3.1139, 2115391, 2646306.
8. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L. The fibronectin isoform containing the ED-B oncofoetal domain: a marker of angiogenesis. Int J Cancer 1994, 59(5):612-618. 10.1002/ijc.2910590507, 7525495.
9. Kosmehl H, Berndt A, Katenkamp D. Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects. Virchows Arch 1996, 429(6):311-322.
10. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, Trachsel E. Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther 2009, 11(5):R142. 10.1186/ar2814, 2787264, 19781067.
11. Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D. Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther 2007, 9(1):R9. 10.1186/ar2115, 1860067, 17261171.
12. Vollmer S, Vater A, Licha K, Gemeinhardt I, Gemeinhardt O, Voigt J, Ebert B, Schnorr J, Taupitz M, Macdonald R, et al. Extra domain B fibronectin as a target for near-infrared fluorescence imaging of rheumatoid arthritis affected joints in vivo. Mol Imaging 2009, 8(6):330-340.
13. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005, 5(6):436-446. 10.1038/nrc1627, 15928674.
14. Zardi L, Neri D. Affinity reagents against tumour-associated extracellular molecules and newforming vessels. Adv Drug Deliv Rev 1998, 31(1-2):43-52. 10.1016/S0169-409X(97)00093-8, 10837617.
15. Mukherjee AB, Zhang Z, Chilton BS. Uteroglobin: a steroid-inducible immunomodulatory protein that founded the Secretoglobin superfamily. Endocr Rev 2007, 28(7):707-725. 10.1210/er.2007-0018, 17916741.
16. Ventura E, Sassi F, Fossati S, Parodi A, Blalock W, Balza E, Castellani P, Borsi L, Carnemolla B, Zardi L. Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins. J Biol Chem 2009, 284(39):26646-26654. 10.1074/jbc.M109.025924, 2785352, 19632988.
17. Thwin MM, Douni E, Aidinis V, Kollias G, Kodama K, Sato K, Satish RL, Mahendran R, Gopalakrishnakone P. Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study. Arthritis Res Ther 2004, 6(3):R282-294. 10.1186/ar1179, 416452, 15142275.
18. Miele L. Antiflammins. Bioactive peptides derived from uteroglobin. Ann N Y Acad Sci 2000, 923:128-140.
19. Miele L, Cordella-Miele E, Facchiano A, Mukherjee AB. Novel anti-inflammatory peptides from the region of highest similarity between uteroglobin and lipocortin I. Nature 1988, 335(6192):726-730. 10.1038/335726a0, 2971881.
20. Miele L, Cordella-Miele E, Facchiano A, Mukherjee AB. Inhibition of phospholipase A2 by uteroglobin and antiflammin peptides. Adv Exp Med Biol 1990, 279:137-160. 10.1007/978-1-4613-0651-1_9, 2151414.
21. Yang SH, Shin SJ, Oh JE, Jin JZ, Chung NH, Lim CS, Kim S, Kim YS. The protective role of uteroglobin through the modulation of tissue transglutaminase in the experimental crescentic glomerulonephritis. Nephrol Dial Transplant 2008, 23(11):3437-3445. 10.1093/ndt/gfn268, 18558621.
22. Sohn J, Kim TI, Yoon YH, Kim JY, Kim SY. Novel transglutaminase inhibitors reverse the inflammation of allergic conjunctivitis. J Clin Invest 2003, 111(1):121-128. 151832, 12511595.
23. Miele L. New weapons against inflammation: dual inhibitors of phospholipase A2 and transglutaminase. J Clin Invest 2003, 111(1):19-21. 151842, 12511581.
24. Borsi L, Balza E, Bestagno M, Castellani P, Carnemolla B, Biro A, Leprini A, Sepulveda J, Burrone O, Neri D, et al. Selective targeting of tumoural vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 2002, 102(1):75-85. 10.1002/ijc.10662, 12353237.
25. Balza E, Borsi L, Allemanni G, Zardi L. Transforming growth factor beta regulates the levels of different fibronectin isoforms in normal human cultured fibroblasts. FEBS Lett 1988, 228(1):42-44. 10.1016/0014-5793(88)80580-5, 3422628.
26. Borsi L, Balza E, Castellani P, Carnemolla B, Ponassi M, Querze G, Zardi L. Cell-cycle dependent alternative splicing of the tenascin primary transcript. Cell Adhes Commun 1994, 1(4):307-317. 10.3109/15419069409097262, 7521758.
27. Borsi L, Balza E, Gaggero B, Allemanni G, Zardi L. The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem 1995, 270(11):6243-6245. 10.1074/jbc.270.11.6243, 7534307.
28. Borsi L, Castellani P, Risso AM, Leprini A, Zardi L. Transforming growth factor-beta regulates the splicing pattern of fibronectin messenger RNA precursor. FEBS Lett 1990, 261(1):175-178. 10.1016/0014-5793(90)80664-5, 2307231.
29. Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998, 273(34):21769-21776. 10.1074/jbc.273.34.21769, 9705314.
30. Carnemolla B, Neri D, Castellani P, Leprini A, Neri G, Pini A, Winter G, Zardi L. Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain. Int J Cancer 1996, 68(3):397-405. 10.1002/(SICI)1097-0215(19961104)68:3<397::AID-IJC20>3.0.CO;2-4, 8903484.